TME Pharma Announces Publication of ESMO Congress 2023 Abstract on the Ongoing NOX-A12 GLORIA Phase
Abstract highlights how NOX-A12 and radiotherapy remodel the immune tumor microenvironment in brain cancer patientsBERLIN--(BUSINESS WIRE)--Regulatory News:TME Pharma N.V. (Euronext Growth Paris: ALTME), a biotechnology company focused on developing novel therapies for treatment of cancer by targeting the tumor micr...
United States Nordrhein Westfalen France General Merck Keytruda Aram Mangasarian Guillaume Van Renterghem
Source: pharmiweb.com